FDA clears Qiagen bloodstream infection panel for U.S. market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
August 10, 2026 4:05 PM EDTQIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel family Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting about 1.7 million adults annually in the U.S., underscoring the need for rapid detection
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE:... More
